{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-24-000031","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.349520+00:00","generated_at":"2026-05-31T09:54:18.043266+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Inhibrx Biosciences reports $1.9B net income in Q2 2024 after separation from former parent","bullets":["Net income of $1.9 billion for Q2 2024, compared to net loss of $47.1 million in Q2 2023","Cash and cash equivalents $226.9M as of June 30, 2024, down from $255.4M at May 30 separation","Separation from Inhibrx, Inc. completed May 30: INBRX-101 transferred to Sanofi for ~$2.2B","Stockholders received $30 cash per share, one $5 CVR, and one Inhibrx Biosciences share per four former parent shares"],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-24-000031","json":"https://secwatch.observer/filing/0002007919-24-000031.json","markdown":"https://secwatch.observer/filing/0002007919-24-000031.md","text":"https://secwatch.observer/filing/0002007919-24-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791924000031/0002007919-24-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791924000031/inhibrx-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:54:18.043266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}